Wayne Kuznar
Wayne Kuznar is a contributor to Urology Times.
Direct plating of rectal cultures improves sensitivity
A screening protocol to guide antibiotic prophylaxis prior to prostate biopsy that eliminates the broth enrichment provides the best sensitivity with the fewest false- positive rates.
Prostate cancer assay may help distinguish aggressive vs. indolent disease
A biopsy-based genomic assay that would discriminate between aggressive prostate cancer and indolent disease to guide treatment decisions is under development.
Less physical, mental exertion with robotic surgery
Standard laparoscopic procedures are associated with more muscular contraction and trapezius muscle fatigue than robot-assisted approaches, according to a comparison of the two approaches conducted by 11 surgeons.
Nerve stimulation 'good option' in refractory voiding dysfunction
An implantable neurostimulator (InterStim, Medtronic, Minneapolis) improves voiding outcomes in patients with voiding dysfunction that is refractory to other therapies, a retrospective long-term follow-up of patients at a single center showed.
Oncologic outcomes similar for robotic, open radical prostatectomy, according to study
In the hands of high-volume surgeons, there is no evidence to suggest that robot-assisted laparoscopic prostatectomy results in worse oncologic outcomes then open radical prostatectomy, even in patients with high-risk cancer.
Prostate tumor volume predicted by urine markers
An interim analysis of a validation study suggests that urine prostate cancer antigen 3 (PCA3) levels and urine TMPRSS2:ERG (T2:ERG) have additive utility in predicting clinically significant prostate tumor volume, and their use together may enhance the selection and monitoring of candidates with low-volume/low-grade disease for active surveillance.
Continuous androgen deprivation therapy shows better survival outcomes in men with metastatic prostate cancer
Continuous androgen deprivation therapy confers a survival advantage over intermittent therapy in men with metastatic prostate cancer.
Irish experience suggests benefits of PSA screening
Widespread PSA screening appears to lead to improvements in pathologic outcomes.
5-alpha-reductase inhibitor use does not compromise PSA utility, study shows
Treatment with the dual 5-alpha- reductase inhibitor dutasteride (Avodart) does not compromise the utility of PSA to detect progression of disease in patients with low-risk localized prostate cancer who are being managed with active surveillance.
Ureteroscopy now used more than shock wave lithotripsy for treating kidney stones
Ureteroscopy has overtaken extracorporeal shock wave lithotripsy as the treatment of choice for kidney stones, Canadian researchers recently reported.